NO20053776L - Diagnostic imaging agents with MMP inhibitory activity - Google Patents

Diagnostic imaging agents with MMP inhibitory activity

Info

Publication number
NO20053776L
NO20053776L NO20053776A NO20053776A NO20053776L NO 20053776 L NO20053776 L NO 20053776L NO 20053776 A NO20053776 A NO 20053776A NO 20053776 A NO20053776 A NO 20053776A NO 20053776 L NO20053776 L NO 20053776L
Authority
NO
Norway
Prior art keywords
diagnostic imaging
inhibitory activity
imaging agents
pharmaceutical composition
matrix metalloproteinases
Prior art date
Application number
NO20053776A
Other languages
English (en)
Other versions
NO20053776D0 (no
Inventor
Alan Cuthbertson
Anthony Eamon Storey
Marivi Mendizabal
Sally-Anne Ricketts
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Duncan Wynn
Julie Davis
Joseph Arukwe
Kirsty Heywood
Ian Wilson
Bodu Levkau
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302891A external-priority patent/GB0302891D0/en
Priority claimed from GB0307524A external-priority patent/GB0307524D0/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20053776D0 publication Critical patent/NO20053776D0/no
Publication of NO20053776L publication Critical patent/NO20053776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)

Abstract

Denne oppfinnelsen gjelder feltet diagnostisk avbilding. Den gjelder især diagnostisk avbilding a sykdommer der det er kjent at spesifikke matriksmetalloproteinaser er involvert. En utforming a oppfinnelsen er en forbindelse med en aktivitet som virker inhibitorisk på matriksmetalloproteinaser o< som egner seg for diagnostisk avbilding. Denne oppfinnelsen legger også frem en farmasøytis sammensetning som omfatter oppfinnelsens kontrastmiddel for diagnostisk avbilding i en form egnet fe administrering til pattedyr. Oppfinnelsen legger videre frem mellomliggende substanser i syntese mellom oppfinnelsens konstrastmidler for diagnostisk avbilding og sett for fremstillingen av oppfinnelsen farmasøytiske sammensetning. Oppfinnelsens farmasøytiske sammensetning kan brukes i diagnosen a sykdommer der det er kjent at spesifikke matriksmetalloproteinaser er involvert.
NO20053776A 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity NO20053776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302891A GB0302891D0 (en) 2003-02-10 2003-02-10 Diagnostic imaging agents for cardiovascular disease
GB0307524A GB0307524D0 (en) 2003-04-01 2003-04-01 Diagnostic imaging agents with MMP inhibitory activity
PCT/GB2004/000524 WO2004069365A1 (en) 2003-02-10 2004-02-10 Diagnostic imaging agents with mmp inhibitory activity

Publications (2)

Publication Number Publication Date
NO20053776D0 NO20053776D0 (no) 2005-08-09
NO20053776L true NO20053776L (no) 2005-09-30

Family

ID=32852413

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053776A NO20053776L (no) 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity

Country Status (8)

Country Link
US (1) US8231858B2 (no)
EP (1) EP1592458A1 (no)
JP (1) JP2006519216A (no)
AU (1) AU2004210208B2 (no)
CA (1) CA2514885A1 (no)
NO (1) NO20053776L (no)
RU (1) RU2005123801A (no)
WO (1) WO2004069365A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
CA2665193C (en) 2006-10-06 2016-02-09 Mallinckrodt Inc. Self-aligning radioisotope elution system
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US8809804B2 (en) * 2011-01-19 2014-08-19 Mallinckrodt Llc Holder and tool for radioisotope elution system
US9153350B2 (en) 2011-01-19 2015-10-06 Mallinckrodt Llc Protective shroud for nuclear pharmacy generators
US8866104B2 (en) 2011-01-19 2014-10-21 Mallinckrodt Llc Radioisotope elution system
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9023318B2 (en) 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013070471A1 (en) * 2011-11-11 2013-05-16 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
EP2644601A1 (en) * 2012-03-28 2013-10-02 Westfälische Wilhelms-Universität Münster Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
WO2001092244A1 (en) * 2000-05-30 2001-12-06 Wayne State University Inhibitors of matrix metalloproteinases

Also Published As

Publication number Publication date
AU2004210208B2 (en) 2007-06-07
EP1592458A1 (en) 2005-11-09
WO2004069365A1 (en) 2004-08-19
WO2004069365A8 (en) 2004-09-30
RU2005123801A (ru) 2006-03-27
NO20053776D0 (no) 2005-08-09
JP2006519216A (ja) 2006-08-24
US8231858B2 (en) 2012-07-31
US20070071670A1 (en) 2007-03-29
CA2514885A1 (en) 2004-08-19
AU2004210208A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
NO20053776L (no) Diagnostic imaging agents with MMP inhibitory activity
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
TNSN07361A1 (en) 3,4-substituted pyrrolidine derivatives for the treatment of hypertension
SV2011003786A (es) Compuestos quimicos 251
SE0001899D0 (sv) New compounds
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005113542A3 (en) N-cyclic sulfonamido inhibitors of gamma secretase
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
UY31180A1 (es) Derivados de (1r, 2r)-n-(1-cianociclopropil)-2-ciclohexanocarboxamidas sustituidas, procedimiento de preparación, composiciones faramacéuticas conteniéndolos y aplicaciones.
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
NO20076053L (no) Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
BRPI0519443A2 (pt) composto orgÂnicos
TW200738698A (en) Organic compounds
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
WO2006094763A8 (en) 3,4,5-substituted piperidine compounds
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application